Review mockup Image: ships as shown Graphic: drawn in code

Laboratory research use only Not for human or veterinary use U.S. only

  1. Home
  2. Legal status

Guide · Regulation · As of November 2026

Is BPC-157 legal in the U.S.?

BPC-157 is not FDA-approved for any use. It is sold in the U.S. labeled for laboratory research use only. In 2023 FDA flagged it as a compounding substance that may present significant safety risks. In July 2026 an FDA advisory committee voted 8–6 to recommend reversing that, but FDA has not finalized any change.1,2

FDA timeline

FDA’s 2023 safety-risk listing still stands. The 2026 committee vote is a recommendation only, and any change requires FDA rulemaking.

  1. FDA places BPC-157 among bulk drug substances for compounding that may present significant safety risks, citing possible immune reactions, peptide impurities and limited safety information.1

  2. FDA’s Pharmacy Compounding Advisory Committee votes 8 to 6, with one abstention, to recommend adding BPC-157 to the list of substances compounding pharmacies may use. FDA’s own review staff had recommended against it.2,3

  3. The vote is advisory. Rulemaking has not been completed, and BPC-157 remains unapproved.2,3

Sport and military

WADA · S0

Prohibited at all times

The World Anti-Doping Agency lists BPC-157 under S0, non-approved substances, prohibited in and out of competition.4

U.S. Department of Defense

Prohibited for service members

Operation Supplement Safety lists BPC-157 as a prohibited peptide and an unapproved drug found in some wellness products.5

What “research use only” means

“Research use only” is a label for materials intended for laboratory work. It is not an FDA approval, and it does not make a product a drug, a dietary supplement or suitable for human use.

This page is general information, not legal advice. Rules can change; check FDA’s current guidance before relying on it.

Sources

  1. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. fda.gov
  2. U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. fda.gov
  3. The Hill. FDA panel votes to add peptides to permitted compounding list despite opposition from agency scientists. July 2026. thehill.com
  4. World Anti-Doping Agency. The Prohibited List. wada-ama.org
  5. Operation Supplement Safety (U.S. Department of Defense). BPC-157: A prohibited peptide and an unapproved drug found in health and wellness products. opss.org
NextFrequently asked questions